Detalles de la búsqueda
1.
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients.
Invest New Drugs
; 41(3): 411-420, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37058183
2.
EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy.
Invest New Drugs
; 40(6): 1342-1349, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36152107
3.
Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
Cancer Sci
; 112(6): 2371-2380, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33686722
4.
Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer.
Int J Clin Oncol
; 26(3): 507-514, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33159605
5.
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Cancer Sci
; 111(3): 932-939, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31961053
6.
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.
BMC Cancer
; 20(1): 207, 2020 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32164651
7.
Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC.
Int J Clin Oncol
; 25(1): 67-73, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31506751
8.
Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients.
Cancer Sci
; 110(10): 3350-3357, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31361375
9.
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
Thorac Cancer
; 15(5): 402-409, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38226415
10.
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.
Thorac Cancer
; 15(10): 788-796, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38400801
11.
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer.
NPJ Precis Oncol
; 8(1): 46, 2024 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38396251
12.
Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors.
JTO Clin Res Rep
; 4(6): 100524, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37426307
13.
Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients.
J Thorac Cardiovasc Surg
; 165(4): 1565-1574.e1, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36137840
14.
MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.
JCI Insight
; 8(24)2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37917191
15.
Clinical characteristics of patients with KRAS mutation detected by liquid biopsy.
Thorac Cancer
; 14(33): 3317-3322, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37751775
16.
GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer.
NPJ Precis Oncol
; 6(1): 16, 2022 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35301419
17.
Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus™ integrated sequencer.
Transl Lung Cancer Res
; 11(5): 711-721, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35693289
18.
A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114).
Thorac Cancer
; 13(9): 1267-1275, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35322551
19.
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation.
JCI Insight
; 7(1)2022 01 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34874919
20.
Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice.
Thorac Cancer
; 12(4): 504-511, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33350072